Kodiak Sciences Inc. (KOD)

Kodiak Sciences Inc. is trading at $99.26, down 0.61% on the session. The 50 day average sits at $48.96 and the 200 day at $37.33, which puts the stock in a uptrend. RSI is at 83.3, which reads as overbought, and MACD is bullish crossover. Volume is below average.

The nearest support is around $87.58 with resistance near $104.00, so that band frames the current range. Average daily movement is roughly $7.06, or about 7.1% of the share price, which is what any stop placement has to allow for. The overall health score of 69 out of 100 combines a trend score of 100, momentum of 66 and a risk score of 24.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.